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Abstract
Patients with diabetes mellitus have an increased risk of developing tuberculosis. Although the underlying mechanism is unclear,
evidence suggests a role for chronic hyperglycaemia. We examined the influence of hyperglycaemia on Mycobacterium
tuberculosis-induced cytokine responses in patients with type 1 diabetes mellitus (T1D). Peripheral blood mononuclear cells
(PBMCs) from 24 male T1D patients with sub-optimal glucose control [HbA1c > 7.0% (53 mmol/L)] and from 24 age-matched
male healthy controls were stimulated with M. tuberculosis lysate. Cytokine analysis, assessment of aerobic glycolysis, receptor
recognition and serum cross-over experiments were performed to explore the mechanistic differences. PBMCs from T1D patients
produced less bioactive interleukin (IL)-1β in response toM. tuberculosis. IL-6 and interferon (IFN)-γ production trended towards a
decrease, whilst other cytokines such as tumour necrosis factor (TNF)-α, IL-17 and IL-1Ra were normal. The decrease in cytokine
production was not correlated to HbA1c or plasma glucose levels. Cross-over serum experiments did not alter the cytokine profile of
T1D or control patients, arguing for an intrinsic cellular defect. Cellular metabolism and the expression of M. tuberculosis-related
pattern recognition receptors (PRRs) such as TLR2, TLR4 and NOD2 did not differ between T1D patients and healthy controls.
Compared to matched controls, T1D patients have a reduced capacity to produce pro-inflammatory cytokines in response to
M. tuberculosis. The impaired IL-1β production in T1D patients may contribute to the increased susceptibility to tuberculosis.
This effect appears not to be related to prevailing glucose levels but to an intrinsic cellular deficit.
Introduction
Diabetes increases the risk of developing active tuberculosis
(TB) and is associated with worsened outcomes during TB
treatment. It has been estimated that 15% of TB cases globally
can be attributed to diabetes [1]. Patients with type 1 diabetes
(T1D) may have an even higher risk of developing TB com-
pared to those with type 2 diabetes (T2D) [2–4]. Additionally,
poor glucose control escalates the risk of TB [5, 6]. The epi-
demiological evidence for the relation between diabetes and
TB is strong, but the molecular and immunological basis for
the susceptibility to TB remains largely unclear.
Recent evidence that points towards a disturbed innate and
adaptive immune response to TB is mainly derived from stud-
ies in T2D patients [7]. However, T2D is a multi-factorial
disease involving age, obesity, sedentary lifestyle and genet-
ics. It is characterised by hyperglycaemia, insulin resistance,
hypertension, dyslipidaemia and oxidative stress. All these
factors, including the use of anti-diabetic drugs with potential
immune-modulating capacities (i.e. metformin), make it diffi-
cult to specifically examine the role of hyperglycaemia in the
increased susceptibility to TB.
Therefore, we sought to study the response to
Mycobacterium tuberculosis in T1D patients with chronic
hyperglycaemia. We excluded individuals using drugs other
than insulin replacement therapy and also those with serious
diabetic complications. We examined whether T1D is
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associated with altered production of pro-inflammatory cyto-
kines such as tumour necrosis factor TNF, interleukin (IL)-1β
and IL-6 from monocytes and interferon (IFN)-γ from CD4+
lymphocytes, all of which are pivotal for effective host de-
fences against TB [8]. Finally, we examined whether external
factors in serum (i.e. hyperglycaemia) or intrinsic factors (i.e.
cellular metabolism and expression of pattern recognition re-
ceptors, PRRs) were responsible for differences in cytokine
responses between healthy controls and T1D patients.
Materials and methods
Recruitment and characterisation of study subjects
We enrolled 24 male T1D patients with an HbA1c > 7.0%
(53 mmol/L) and 24 age-matched male healthy controls.
Participants were all between 20 and 70 years old. For T1D
patients, the minimal duration of diabetes was 1 year. Patients
using medication other than insulin were excluded. HbA1c
was measured by standard laboratory methods. Plasma insulin
was measured by radioimmunoassay [9]. Plasma cholesterol,
triglyceride (TG), glucose (Liquicolor; Human GmbH,
Wiesbaden, Germany) and free fatty acids (NEFA C;
WAKO Chemicals, GmbH, Neuss, Germany) were measured
enzymatically following the manufacturers’ protocols. Blood
was drawn from a cubital vein and collected into sterile EDTA
tubes for isolation of peripheral blood mononuclear cells
(PBMCs) or from serum tubes (BD Biosciences, Franklin
Lakes, NJ, USA). The study was approved by the institutional
review board and written informed consent was obtained from
all subjects. Using similar criteria, an additional six T1D and
six controls were recruited for a follow-up experiment.
PBMC isolation and stimulation
PBMC isolation was performed by dilution of blood in
pyrogen-free phosphate-buffered saline (PBS) and differential
density centrifugation over Ficoll-Paque (GE Healthcare,
Zeist, The Netherlands). Cells were washed twice in PBS
and re-suspended in RPMI culture medium (Roswell Park
Memorial Institute medium; MP Biomedicals, Santa Ana,
CA, USA) supplemented with 5 mM glucose, 10 μg/mL gen-
tamicin, 10 mM L-glutamine and 10 mM pyruvate. PBMCs
were counted with a Coulter counter (Beckman Coulter,
Fullerton, CA, USA) and adjusted to 5 × 106 cells/mL. A
100-μL volume was added to round-bottom 96-well plates
(Corning, New York, USA) for PBMC stimulation experi-
ments. Excess unstimulated PBMCs were lysed in TRIzol
reagent (Invitrogen, Breda, The Netherlands) and stored at
− 80 °C until RNA isolation was performed.
Cells were stimulatedwith RPMI, 1 μg/mLM. tuberculosis
(H37Rv) lysate for 24 h or 7 days (in the presence of 10%
human pool serum for lymphocyte-derived cytokines). For
serum cross-over experiments, cells were incubated with
25% serum for 24 h or 7 days. In a follow-up experiment,
we collected six additional male T1D patients with an
HbA1c > 7.0% and six age-matched male healthy controls.
PBMCs were isolated and stimulated with Escherichia coli
lipopolysaccharide (LPS) (from E. coli serotype 055:B5;
Sigma-Aldrich, St. Louis, MO, USA; 1 ng/mL or 10 ng/ml).
Supernatants were collected and stored at − 20 °C until
cytokine/lactate measurements were performed.
Cytokine measurements
Cytokine measurements from cell culture supernatants were
performed by enzyme-linked immunosorbent assay (ELISA);
namely, IL-1β, IL-1 receptor antagonist (IL-1Ra), TNF-α
(R&D Systems, Minneapolis, MN, USA) and IL-6
(Sanquin, Amsterdam, The Netherlands) were measured in
the 24-h PBMC stimulation experiments. Supernatants of
the 7-day stimulations were used to measure IL-22, IL-17
(R&D Systems) or IFN-γ (Sanquin).
Bioactive IL-1 assay
Active IL-1 was measured indirectly using the mouse
thymoma EL4-NOB1 (NOB1) cell line. NOB1 cells were
cultured in RPMI culture medium supplemented with 1 mM
pyruvate, 1 mM GlutaMAX, 1 mM penicillin/streptomycin
and 10% foetal bovine serum (Gibco, Burlington, Ontario,
Canada) until confluence was reached. NOB1 cells (105
cells/well) were plated in a flat-bottom 96-well plate
(Corning). 70 μL (2× dilution) of supernatant from PBMCs
of T1D or healthy controls that were stimulated with
M. tuberculosis were added to each well. Cytokine measure-
ment for murine IL-2 was performed by ELISA (R&D
Systems).
Lactate measurements
Lactate was measured from cell culture supernatants using a
coupled enzymatic assay in which lactate was oxidised and
the resulting H2O2 was coupled to the conversion of
Amplex® Red reagent to fluorescent resorufin by horseradish
peroxidase (HRP). 30 μL of lactate standard or 200-fold di-
luted sample was added to a black 96-well flat-bottom plate,
followed by 30 μL of reaction mix, which consisted of 0.6 μL
of 10 U/mL HRP (Sigma-Aldrich), 0.6 μL of 100 U/mL lac-
tate oxidase (Sigma-Aldrich), 0.3 μL of 10 mM Amplex®
Red reagent (Life Technologies, Carlsbad, CA, USA) and
28.5 μL PBS. The assay was incubated for 20 min at room
temperature (RT) and the fluorescence of resorufin (excita-
tion/emission maxima = 570/585 nm) was measured on a
96-well plate reader (BioTek, Winooski, VT, USA).
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Transcriptional analysis of isolated PBMCs
RNA was isolated from unstimulated PBMCs using TRIzol
reagent (Invitrogen), according to the manufacturer’s proto-
col. RNA was transcribed into complementary DNA by
reverse-transcription using the iScript cDNA Synthesis Kit
(Bio-Rad, Hercules, CA, USA). Quantitative real-time poly-
merase chain reaction (qPCR) was performed using different
primer sets (Biolegio, Malden, The Netherlands); primer se-
quences for hexokinase (HK) 2, HK3, 6-phosphofructo-2-ki-
nase/fructose-2,6-biphosphatase 3 (PFKFB3), pyruvate dehy-
drogenase kinase 4 (PDK4), malate dehydrogenase (MDH) 1,
MDH2, toll-like receptor (TLR) 2, TLR4, nucleotide-binding
oligomerisation domain containing 2 (NOD2), caspase re-
cruitment domain family member 9 (CARD9), receptor
interacting serine/threonine kinase 2 (RIPK2), mitogen-
activated protein kinase 9 (MAPK9), TNF receptor-
associated factor 6 (TRAF6) and caspase 1 (CASP-1) are giv-
en in Supplementary Table 1. Power SYBR Green PCR
Master Mix (Applied Biosystems, Carlsbad, CA, USA) was
used for qPCR in a StepOnePlus Real-Time PCR System
(Applied Biosystems). qPCR data were normalised to the
housekeeping gene human β2M.
Statistics
Data are shown as means ± standard error of the mean
(SEM). Differences in cytokine secretion were calculated
Table 1 Descriptive characteristics of the studied type 1 diabetes (T1D)
patients and controls
T1D patients Controls p-Value
Number 24 24
Age (years) 48.1 ± 2.7 47.5 ± 2.6 0.91
Duration of diabetes (years) 24.2 ± 2.5 – –
Glucose (mmol/L) 9.3 ± 0.8 4.6 ± 0.2 < 0.001***
HbA1c (%) 8.9 ± 0.3 5.4 ± 0.1 < 0.0001***
Insulin (mE/L) 31.5 ± 3.8 19.9 ± 2.9 < 0.05*
Cholesterol (mmol/L) 3.5 ± 0.1 4.0 ± 0.2 0.05
TG (mmol/L) 1.36 ± 0.15 1.25 ± 0.12 0.70
FFA (mmol/L) 0.25 ± 0.04 0.25 ± 0.04 0.39
Data are mean ± standard error of the mean (SEM). FFA, free fatty acids;
HbA1c, glycosylated haemoglobin; TG, triglyceride
Fig. 1 Peripheral bloodmononuclear cells (PBMCs) from type 1 diabetes
mellitus (T1D) subjects secrete less interleukin (IL)-1β upon stimulation
with Mycobacterium tuberculosis. PBMCs (5 × 105/well) from T1D
patients and healthy control subjects were stimulated with 1 μg/mL
M. tuberculosis lysate. Secretion of: a IL-1β, b IL-6, c IL-1Ra and d
tumour necrosis factor (TNF)-α were measured in supernatants by
enzyme-linked immunosorbent assay (ELISA) after 24 h of stimulation.
e Interferon (IFN)-γ, f IL-17 and g IL-22 were measured after 7 days of
stimulation. Data are mean ± standard error of the mean (SEM) from n =
24 individuals per group. **p < 0.01 compared with matched healthy
controls
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using the Mann–Whitney test for two independent sam-
ples. Correlation analysis between glucose metabolites
and cytokine secretion was performed using Spearman’s
rank correlation coefficient and the 95% confidence inter-
val was calculated accordingly. A p-value of < 0.05 was
considered statistically significant. Generation of graphs
and statistical analyses were performed using GraphPad
Prism 5.
Results
The participant’s characteristics are shown in Table 1. Age,
plasma TG and free fatty acid (FFA) levels were not differ-
ent between T1D patients and the 24 control subjects
(Table 1). As per definition, HbA1c and plasma glucose
levels were significantly increased in T1D patients com-
pared to healthy controls. Plasma insulin levels were also
higher, whilst plasma cholesterol levels were lower in T1D
patients.
PBMCs of T1D patients show reduced
pro-inflammatory IL-1β cytokine secretion
in response to M. tuberculosis
No spontaneous cytokine production was detected in
unstimulated TID patients or control cells (RPMI; Fig. 1). In
contrast, robust induction of cytokine production was ob-
served in response to M. tuberculosis in both groups. The
production of IL-1β was significantly lower in T1D patients
as compared to healthy controls (p < 0.01; Fig. 1). IL-6 and
IFN-γ followed a similar trend, albeit at borderline signifi-
cance (p = 0.06). TNF-α, IL-1Ra, IL-17 and IL-22 levels were
not different between T1D patients and controls (Fig. 1). The
decrease in IL-1β production was not specific to
M. tuberculosis stimulation. Six additionally recruited T1D
A
B
Fig. 2 Correlation of cytokine
secretion with glycaemia.
Associations for T1D patients
between glycated haemoglobin
(HbA1c%), plasma glucose levels
and secretion of IL-1β, IL-6 and
IFN-γ from PBMCs after
stimulation with 1 μg/mL
M. tuberculosis lysate. a
Spearman’s rank correlation
coefficients for all associations. b
Correlations are shown by linear
fitted curves and 95% confidence
intervals for T1D subjects (n =
24)
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patients also produced lower levels of IL-1β in response to
high-dose LPS stimulation (Supplementary Fig. 1).
Correlation of IL-1β cytokine secretion with glycaemia
To determine whether the lower cytokine production in
PBMCs from T1D patients in response to M. tuberculosis
stimulation was related to glucose control, cytokine produc-
tion was correlated with HbA1c and glucose. However, there
were no correlations betweenM. tuberculosis-induced IL-1β,
IL-6 or IFN-γ secretion from PBMCs and HbA1c or plasma
glucose levels of T1D patients (Fig. 2). Also, no correlations
were found between cytokine secretion and duration of diabe-
tes (Supplementary Fig. 2). IL-1β secretion strongly correlat-
ed with IL-6 secretion in response toM. tuberculosis, but there
were no other correlations between cytokine responses.
Influence of serum and cellular metabolism
on cytokine production
The cross-over of autologous serum from control to T1D and
vice versa did not influence cytokine production of either sub-
ject group (Fig. 3). This suggests that the reduced IL-1β se-
cretion is not directly related to plasma glucose concentration
or other serum factors; instead, it is likely to be an intrinsic
defect within the immune cells of T1D patients.
Activation of aerobic glycolysis is important for cytokine
production in response to M. tuberculosis [10]. However,
lactate production, a marker of glycolysis, was not decreased
in T1D patients. In fact,M. tuberculosis stimulation increased
lactate production in T1D patients compared to matched
healthy controls (Fig. 4a). Glucose consumption (Fig. 4b)
and the expression levels of glycolysis genes HK2, HK3 and
PFKFB3 in PBMCs was similar between T1D patients and
healthy controls (Fig. 4e–g). Finally, no difference in the ex-
pression of the TCA cycle genes PDK4, MDH1 and MDH2
(Fig. 4h–j) was observed.
Mycobacterium tuberculosis recognition
and downstream signalling
To determine whether changes in receptors involved in
M. tuberculosis recognition could explain the impaired cyto-
kine response of PBMCs from T1D patients, we investigated
the gene expression levels of well-known M. tuberculosis
PRRs in PBMCs of both groups. Levels of TLR2, TLR4
and NOD2 were unchanged (Fig. 5a–c). In addition, no dif-
ferences were found in the expression of genes involved in the
intracellular signalling response to M. tuberculosis, including
CARD9, RIPK2, MAPK9, TRAF6 and CASP1 (Fig. 5d–h).
Bioactive IL-1 secretion from PBMCs of T1D patients
To determine whether differences in cellular processing affect-
ed the secretion of IL-1β, we determined the amount of bio-
active IL-1 in the supernatants of PBMCs stimulated with
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Fig. 3 Influence of T1D serum on cytokine production in response to
M. tuberculosis. PBMCs (5 × 105 cells/well) of healthy control (CON)
subjects were incubated in either 25% of autologous serum or 25% of
serum from an age-matched type 1 diabetes (T1D) subject and vice versa
for PBMCs from T1D subjects. Secretion of: a IL-1β, b IL-6 and c TNF-
α were measured in the supernatants using ELISA after 24 h of exposure
toM. tuberculosis. d INF-γ, e IL-22 and f IL-17 were determined after 7
days. Data are mean ± SEM from n = 24 individuals per group. *p < 0.05
compared with healthy controls
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M. tuberculosis from Fig. 1 (Fig. 6). We found that PBMCs of
T1D patients released significantly lower levels of bioactive
IL-1 in response to M. tuberculosis .
Discussion
The primary finding of this study is that PBMCs from patients
with T1D have a reduced ability to produce IL-1β, IL-6 and
IFN-γ in response to M. tuberculosis stimulation, while TNF,
IL-17 and IL-1Ra production is normal. These changes may be
partly responsible for the well-known susceptibility of patients
with diabetes for TB. The current data suggest that the decreased
cytokine production after stimulation with M. tuberculosis is an
intrinsic cellular deficit in PBMCs from T1D patients, since dif-
ferences in cytokine secretion were not due to external factors in
serum or related to glucose regulation.
Epidemiological studies that investigated the relation be-
tween hyperglycaemia and the risk for TB have been contra-
dicting. Both a positive effect [5, 6] and no effect [11–13] of
Fig. 4 Cellular metabolism in
PBMCs from T1D subjects and
controls. a Lactate secretion and c
glucose consumption were
measured in the supernatant of
unstimulated (RPMI) PBMCs of
type 1 diabetes (T1D) and healthy
control (CON) subjects as well as
b, d after 24 h of stimulation with
M. tuberculosis lysate. Relative
mRNA expression values of e
HK2, f HK3, g PFKFB3, h
PDK4, i MDH1 and j MDH2 in
unstimulated PBMCs from T1D
andCON subjects. Data aremean
± SEM from n = 24 individuals
per group
376 Eur J Clin Microbiol Infect Dis (2018) 37:371–380
hyperglycaemia on the risk for TB have been described. These
studies vary greatly in size, geography and definition of con-
trolled versus uncontrolled glycaemia. To our knowledge, this
is the first study specifically examining the cytokine produc-
tion capacity of T1D patients to M. tuberculosis. At the same
time, studies on the cytokine response to other pathogenic
stimuli such as LPS strongly support our findings. Ex vivo
stimulation experiments performed in both T1D [14–16] and
T2D [17, 18] patients describe a similar decrease of IL-1β and
IL-6 but not TNF-α, IL-1Ra and IFN-γ production, respec-
tively. As shown in the stimulation experiments with LPS, this
decrease in cytokine signalling is not specific for
M. tuberculosis, thus supporting the notion that an intrinsic
defect in cytokine production rather than an M. tuberculosis-
specific signalling defect is the mechanism underlying the
decrease in cytokine production. This may also explain why
T1D patients are also susceptible to other (common) infec-
tions, such as lower respiratory tract infection, urinary tract
infection, and skin and mucous membrane infection [19, 20].
Interestingly, patients with both TB and diabetes produce
more cytokines compared to patients with only TB [21, 22].
Together, these findings suggest an initial sub-optimal re-
sponse to infection which promotes bacterial growth and sub-
sequent pathology. This hypothesis of a delayed immune re-
sponse is supported by a mouse model of concomitant TB and
diabetes disease [23].
The exact type of intracellular defects remains to be eluci-
dated. No change in aerobic glycolysis was observed nor al-
tered expression of relevant PRRs. It is possible that a certain
level of accelerated immunosenescence occurs in T1D. This
process, described for aging, is characterised by impaired cel-
lular immune function (leading to increased death due to in-
fectious diseases), simultaneously with increased chronic in-
flammatory activity (leading to increased incidence of cardio-
vascular disease) [24]. The observations that T1D patients
show enhanced low-grade chronic inflammation and cardio-
vascular diseases [25] and, at the same time, an impaired im-
mune response to pathogens as observed in the current study
support this hypothesis. The decrease in IL-6 may be a sec-
ondary effect as IL-1β induces IL-6 production in a paracrine
signalling loop. Similarly, IL-18, another product of caspase-1
activity, is important for IFN-γ production. This could explain
Fig. 5 Mycobacterium
tuberculosis recognition and
downstream signalling. Relative
basal mRNA expression values of
PBMCs from type 1 diabetes
(T1D) patients are shown when
compared to matched healthy
controls (CON) for a TLR2, b
TLR4, c NOD2, d CARD9, e
RIPK2, fMAPK9, g TRAF6 and
h CASP1. Data are mean ± SEM
from n = 24 individuals per group
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why the decrease in these cytokines is more subtle as com-
pared to IL-1β. This avenue will form a cornerstone for fur-
ther research.
The implications of a decrease in IL-1β production for sus-
ceptibility to TB are significant. In a murine model of TB, IL-
1α/β double knockout mice [26] or mice deficient in IL-1R1
[27] display increased susceptibility to M. tuberculosis infec-
tion. Although the spectra of human and mouse TB do not
completely overlap, there are firm established points of conver-
gence [28]. Therefore, these mouse studies suggest that IL-1
has an important role in the generation of an adequate host
defence against TB. In humans, a positive association between
IL-1β levels and resistance to TB was inferred from human
IL1B gene polymorphisms [29]. Moreover, patients with gain-
of-functionmutations in the inflammasome component NLRP3
have an increased capacity to kill M. tuberculosis [30].
Mechanistically, a recent study elucidated that IL-1β promoted
bacterial containment through the induction of specific eicosa-
noids that limited excessive type 1 IFN-γ production [31]. The
current study was performed in T1D patients, with chronic
hyperglycaemia as a key characteristic. The observed impaired
cellular cytokine response could be similar for T2D patients.
However, T2D is a much more heterogeneous disease
characterised by multiple metabolic disturbances (i.e.
hyperglycaemia, insulin resistance, hypertension,
dyslipidaemia and oxidative stress), which may further
contribute to the increased susceptibility to TB andwhich needs
further investigation.
As a limitation of this study, we did not investigate other
host defence mechanisms such as phagocytosis, reactive oxy-
gen species (ROS) or nitric oxide (NO) production from
monocytes or macrophages, since it is unlikely that reduced
IL-1β is the sole factor in susceptibility to TB. A confounding
factor in the current study could be the significantly higher
levels of insulin in blood of T1D patients, as insulin can affect
cytokine production; however, we did not find any correlation
between insulin and cytokine production in T1D patients
(Supplementary Fig. 3). Lastly, another limitation of this study
is the relatively small size of our cohort, as a result of which
subtle associations such as those between glucose control and
cytokine responses may not be detectable. We chose to study
only male patients and healthy controls in order to reduce
variability in the cytokine response as much as possible, hence
enabling the generation of robust results with 24 individuals
per group. Indeed, for example, oral contraceptive usage in
women has been shown to significantly impact on cytokine
secretion from PBMCs [32]. Although we cannot completely
exclude differences of cytokine production between male and
female diabetes patients, no differences have been observed
previously between healthy men and women regarding the IL-
1β response to M. tuberculosis [32], suggesting that our re-
sults derived from male participants are most likely relevant
for both men and women.
In conclusion, this study specifically identifies a decrease
in bioactive IL-1β to possibly be, due to a deficit in intracel-
lular processing rather than chronic hyperglycaemia, a strong
candidate in the susceptibility of T1D patients to TB.
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Fig. 6 Bioactive IL-1 secretion from PBMCs of T1D patients. PBMCs
(5 × 105/well) from type 1 diabetes patients (T1D) and healthy control
subjects (CON) were stimulated with 1 μg/mL M. tuberculosis lysate
for 24 h and supernatants were subsequently incubated with the murine
thymoma EL4-NOB1 cell line (105 cells/well). Mouse IL-2 cytokine
secretion in response to present bioactive IL-1 in the supernatant of the
PBMCs was measured using ELISA. Data are mean ± SEM from n = 24
individuals per group. *p < 0.05 compared with the matched healthy
controls
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